Phathom Pharmaceuticals(US:PHAT) Globenewswire·2025-10-23 12:00Core Insights - Phathom Pharmaceuticals is participating in the ACG 2025 Annual Scientific Meeting to showcase its leadership in gastrointestinal treatments, particularly focusing on VOQUEZNA (vonoprazan) for GERD [1][2][3] Company Activities - The company will engage with the medical community through a product theater presentation on VOQUEZNA and will have a significant presence at the exhibit floor [2][3] - Phathom has organized an independent medical education program titled "Decision Points in the Management of GERD," scheduled for October 25, 2025 [5] Product Information - VOQUEZNA is a potassium-competitive acid blocker (PCAB) approved for treating various forms of GERD, including Erosive GERD and Non-Erosive GERD [6][25] - The product is marketed in the U.S. for multiple indications, including the relief of heartburn associated with Non-Erosive GERD and the healing of Erosive GERD [25] Safety and Efficacy - VOQUEZNA has been associated with several adverse reactions, including gastritis (3% in healing of Erosive GERD) and diarrhea (2% in relief of heartburn associated with Non-Erosive GERD) [20][21] - Important safety information includes contraindications for patients with hypersensitivity to vonoprazan and potential risks such as acute tubulointerstitial nephritis and Clostridioides difficile-associated diarrhea [6][10][11] Market Position - The company aims to build on the momentum for VOQUEZNA in the GERD treatment market by connecting with healthcare professionals and sharing clinical insights at the ACG meeting [3][25]